Formulation Licenses
Registered finished dosage forms (FDF), transferable tech packages and in-development in-licensing pipelines · delivered per target-market approval pathway
Formulation (FDF)
Exemestane Tablets
Tablets · 25mg
- Therapy
- Oncology
- Status
- Official FDF licensing catalog (UB216)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Dapagliflozin/Metformin Hydrochloride Sustained-release Tablets
Sustained-release Tablets · 10mg/1000mg; 5mg/1000mg; 2.5mg/1000mg
- Therapy
- Metabolic & Endocrinology
- Status
- Official FDF licensing catalog (UB215)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Olaparib Tablets
Tablets · 100mg; 150mg
- Therapy
- Oncology
- Status
- Official FDF licensing catalog (UB214)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Sitagliptin/Metaformin Hydrochloride Sustained-release Tablets
Sustained-release Tablets · 50mg/500mg; 50mg/850mg
- Therapy
- Metabolic & Endocrinology
- Status
- Official FDF licensing catalog (UB213)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Pregabalin Extended-release Tablets
Tablets · 82.5mg; 165mg; 330mg
- Therapy
- Neurology
- Status
- Official FDF licensing catalog (UB212)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Macitentan Tablets
Tablets · 10mg
- Therapy
- Respiratory
- Status
- Official FDF licensing catalog (UB211)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Propafenone Hydrochloride Extended-release Capsules
Capsules · 225mg; 325mg; 425mg
- Therapy
- Cardiovascular
- Status
- Official FDF licensing catalog (UB210)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Sevelamer Carbonate Tablets
Tablets · 800mg
- Therapy
- Nephrology & Urology
- Status
- Official FDF licensing catalog (UB209)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States, Philippines
Formulation (FDF)
Tofacitinib Citrate Sustained-release Tablets
Sustained-release Tablets · 11mg; 22mg
- Therapy
- Immunology & Inflammation
- Status
- Official FDF licensing catalog (UB208)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Ursodeoxycholic Acid Capsules
Capsules · 250mg
- Therapy
- Gastroenterology & Hepatology
- Status
- Official FDF licensing catalog (UB207)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- To be assessed
Formulation (FDF)
Mesalazine Delayed-release Tablet
Tablet · 1.2g
- Therapy
- Gastroenterology & Hepatology
- Status
- Official FDF licensing catalog (UB206)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Paroxetine Hydrochloride Enteric-coated Sustained-release Tablets
Sustained-release Tablets · 12.5mg; 25mg
- Therapy
- Others > Psychiatry
- Status
- Official FDF licensing catalog (UB205)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Posaconazole Enteric-coated Tablets
Tablets · 100mg
- Therapy
- Infectious Diseases
- Status
- Official FDF licensing catalog (UB203)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States, Australia, Singapore…
Formulation (FDF)
Isavuconazonium Sulfate for Injection
for Injection · 200mg
- Therapy
- Infectious Diseases
- Status
- Official FDF licensing catalog (UB201)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
cEnteric-coated Tablets
Tablets · 500mg
- Therapy
- Gastroenterology & Hepatology
- Status
- Official FDF licensing catalog (UB200)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Mesalazine Gastro-Resistant Prolonged-Release Granules
— · 0.5g; 1.5g
- Therapy
- Gastroenterology & Hepatology
- Status
- Official FDF licensing catalog (UB199)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Carbamazepine Extended-Release Tablets
Tablets · 100mg; 200mg; 400mg
- Therapy
- Neurology
- Status
- Official FDF licensing catalog (UB198)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Tamsulosin Hydrochloride Capsules
Capsules · 0.4mg
- Therapy
- Others > Men's Health
- Status
- Official FDF licensing catalog (UB197)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Bupropion Hydrochloride Extended-Release Tablets
Tablets · 150mg; 300mg
- Therapy
- Others > Psychiatry
- Status
- Official FDF licensing catalog (UB196)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Montelukast Sodium Tablets
Tablets · 10mg
- Therapy
- Respiratory
- Status
- Official FDF licensing catalog (UB195)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Montelukast Sodium Chewable
— · 4mg; 5mg
- Therapy
- Respiratory
- Status
- Official FDF licensing catalog (UB194)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Glucagon Nasal Powder
— · 3mg
- Therapy
- Metabolic & Endocrinology
- Status
- Official FDF licensing catalog (UB193)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States, EU, Japan
Formulation (FDF)
Epinephrine Inhalation Aerosol
— · 0.125mg
- Therapy
- Respiratory
- Status
- Official FDF licensing catalog (UB192)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- United States
Formulation (FDF)
Ilaprazole Sodium for Injection
for Injection · 10mg
- Therapy
- Gastroenterology & Hepatology
- Status
- Official FDF licensing catalog (UB188)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Semaglutide Injection
Injection · 1.34mg/ml, 3ml; 1.34mg/ml, 1.5ml
- Therapy
- Metabolic & Endocrinology
- Status
- Official FDF licensing catalog (UB175)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Iohexol Injection
Injection · 100ml:35g
- Therapy
- Others > Medical Devices & Diagnostics
- Status
- Official FDF licensing catalog (UB173)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- To be assessed
Formulation (FDF)
Empagliflozin Tablets
Tablets · 10mg; 25mg
- Therapy
- Metabolic & Endocrinology
- Status
- Official FDF licensing catalog (UB172)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Paclitaxel Injection
Injection · 5ml: 30mg; 16.7ml: 100mg
- Therapy
- Oncology
- Status
- Official FDF licensing catalog (UB171)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Cefoxitin Sodium for Injection
for Injection · 1.0g
- Therapy
- Infectious Diseases
- Status
- Official FDF licensing catalog (UB170)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Zoledronic Acid Concentrated Solution for Injection
for Injection · 5ml: 4mg
- Therapy
- Oncology
- Status
- Official FDF licensing catalog (UB169)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Pradefovir Mesylate Tablets
Tablets · 45mg
- Therapy
- Gastroenterology & Hepatology
- Status
- Official FDF licensing catalog (UB168)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Tacrolimus XR
— · 0.5mg; 1mg
- Therapy
- Immunology & Inflammation
- Status
- Official FDF licensing catalog (UB162)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Leuprorelin Acetate Microspheres for Injection
Microspheres for Injection · 3.75mg
- Therapy
- Oncology
- Status
- Official FDF licensing catalog (UB161)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Pregabalin Capsules
Capsules · 75mg; 150mg
- Therapy
- Anesthesiology
- Status
- Official FDF licensing catalog (UB160)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Dexmedetomidine Hydrochloride Injection
Injection · 1ml: 0.1mg; 2ml: 0.2mg
- Therapy
- Neurology
- Status
- Official FDF licensing catalog (UB159)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- EU, China
Formulation (FDF)
Parecoxib Sodium for Injection
for Injection · 40mg
- Therapy
- Anesthesiology
- Status
- Official FDF licensing catalog (UB157)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- EU, China, Malaysia
Formulation (FDF)
Tofacitinib Citrate Tablets
Tablets · 5mg
- Therapy
- Others > Rheumatology
- Status
- Official FDF licensing catalog (UB156)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- To be assessed
Formulation (FDF)
Triamcinolone Acetonide and Econazole Nitrate Cream
Cream · 16.5mg: 150mg
- Therapy
- Others > Dermatology
- Status
- Official FDF licensing catalog (UB154)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Metformin Hydrochloride and Glipizide Tablets
Tablets · 250mg/2.5mg
- Therapy
- Metabolic & Endocrinology
- Status
- Official FDF licensing catalog (UB153)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Mecobalamin Tablets
Tablets · 0.5mg
- Therapy
- Neurology
- Status
- Official FDF licensing catalog (UB152)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Epalrestat Tablets
Tablets · 50mg
- Therapy
- Metabolic & Endocrinology
- Status
- Official FDF licensing catalog (UB151)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Fondaparinux Sodium Injection
Injection · 0.5ml: 2.5mg
- Therapy
- Others > Blood and Blood Forming Organs
- Status
- Official FDF licensing catalog (UB150)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Extract of Ginkgo Biloba Leaves Injection
Injection · 5ml:17.5mg (4.2mg flavone glycoside)
- Therapy
- Neurology
- Status
- Official FDF licensing catalog (UB142)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Protamine Sulfate Injection
Injection · 5ml: 50mg; 10ml: 100mg
- Therapy
- Other
- Status
- Official FDF licensing catalog (UB141)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Human Albumin
— · 5g/vial (5%, 100mL); 5g/vial (20%, 25mL); 10g/vial (20%, 50mL); 12.5g/vial (25%, 50mL)
- Therapy
- Cardiovascular
- Status
- Official FDF licensing catalog (UB133)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Human Coagulation Factor VIII
— · 200IU
- Therapy
- Cardiovascular
- Status
- Official FDF licensing catalog (UB132)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Human Prothrombin Complex
— · 400IU factor IX, 400IU factor II, 200IU factor VIII, 400IU factor X
- Therapy
- Cardiovascular
- Status
- Official FDF licensing catalog (UB131)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China
Formulation (FDF)
Human Fibrinogen
— · 0.5g/vial
- Therapy
- Cardiovascular
- Status
- Official FDF licensing catalog (UB130)
- Registration
- Registered (market rights transferable / DCP·NP per market)
- Markets
- China